Ketan Laud, MD
Ophthalmology · Massapequa, NYNPI 1114151537
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $263,565 of the $289,658 with a category attached, or 91.0%. Mallinckrodt Hospital Products Inc. accounts for 74.7% of it on its own, with 28 other manufacturers making up the rest. Among ophthalmology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 458 payments — averaging $632.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$216K
- Astellas Pharma US Inc$44K
- Genentech USA, Inc.$18K
- ANI Pharmaceuticals, Inc.$5K
- Regeneron Healthcare Solutions, Inc.$2K
- AbbVie$805
- plus $3K from 23 others
Across 220 payments — averaging $1965.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$349K
- Astellas Pharma Global Development$74K
- Bayer$9K
What the payments were for
- Consulting fees$3,8001%
- Speaking & faculty fees$263,56591%
- Travel & lodging$7,7553%
- Food & beverage$14,3825%
- Education$1160%
- Gifts$410%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 149 | $216,481 |
| Astellas Pharma US Inc | 51 | $43,829 |
| Genentech USA, Inc. | 45 | $18,469 |
| ANI Pharmaceuticals, Inc. | 19 | $5,274 |
| Regeneron Healthcare Solutions, Inc. | 61 | $1,716 |
| AbbVie(2 entities) | 39 | $805 |
| Bausch & Lomb Americas Inc. | 14 | $455 |
| Mallinckrodt Enterprises LLC | 8 | $358 |
| Alimera Sciences, Inc. | 7 | $259 |
| Apellis Pharmaceuticals, Inc. | 7 | $229 |
| Aerie Pharmaceuticals, Inc. | 5 | $195 |
| Novartis | 7 | $190 |
| Eyepoint US, Inc. | 4 | $190 |
| Oculus Surgical Inc. | 2 | $183 |
| Dompe US, Inc. | 2 | $157 |
| Harrow Eye, LLC | 4 | $121 |
| Sun Pharmaceutical Industries Inc. | 5 | $105 |
| Coherus Oncology, Inc. | 3 | $98 |
| Alcon | 5 | $93 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $92 |
| Oyster Point Pharma, Inc. | 3 | $80 |
| Kala Pharmaceuticals, Inc. | 4 | $80 |
| Amgen(2 entities) | 3 | $56 |
| Regeneron | 1 | $44 |
| Biotissue Holdings Inc. | 1 | $26 |
| Beaver-visitec International, Inc. | 1 | $23 |
| Shire North American Group Inc | 1 | $19 |
| Thea Pharma Inc. | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$289,658 in reported general payments places this provider in the 95th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 14 | $18,080 |
| Prednisolone Acetate | 288 | $9,586 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $8,415 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 12 | $3,967 |
| Brimonidine Tartrate | 39 | $1,723 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $1,485 |
| Ketorolac Tromethamine | 100 | $1,380 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 83 | $1,366 |
| Latanoprost | 88 | $1,111 |
| Timolol Maleate | 32 | $874 |
| Ofloxacin | 62 | $645 |
| Atropine Sulfate | 15 | $402 |
| Dorzolamide Hcl | 18 | $218 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $805 | $26,49533 claims |
| AlconSimbrinza | $93 | $3,96712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Massapequa
- Eric SiglerMassapequa$350K
- David RubaltelliBrooklyn$8.9M
- Nathan RadcliffeNew York$2.1M
- Richard SpaideNew York$1.7M
- Eric DonnenfeldGarden City$1.4M
- Marguerite McDonaldOceanside$893K
- Joshua YoungNew York$814K
- David KleinmanRochester$730K
- Jonathan JonischGreat Neck$726K
- Joseph PanarelliNew York$541K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.